# CPX-351 Plus Enasidenib for Relapsed AML

> **NCT03825796** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 2 (actual)

## Conditions studied

- Recurrent Acute Myeloid Leukemia

## Interventions

- **DRUG:** Enasidenib Mesylate
- **DRUG:** Liposome-encapsulated Daunorubicin-Cytarabine

## Key facts

- **NCT ID:** NCT03825796
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-04-12
- **Primary completion:** 2024-09-01
- **Final completion:** 2024-09-01
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2023-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03825796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03825796, "CPX-351 Plus Enasidenib for Relapsed AML". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03825796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*